Toyonori Tsuzuki
Aichi Medical University
297 Papers
616 Citations
Toyonori Tsuzuki is an academic researcher from Aichi Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 30, co-authored 207 publications.
Chat about Author
Papers
Immunocytochemical analysis for differential diagnosis of thyroid lesions using liquid-based cytology.
Katsunori Hashimoto,Ayumi Morimoto,Makoto Kato,Yoshihiro Tominaga,Nagako Maeda,Toyonori Tsuzuki,Toyoharu Yokoi,Tetsuro Nagasaka +7 more
TL;DR: The panel in this study is useful for more objective and accurate diagnosis of thyroid cytology and its sensitivity, specificity and diagnostic accuracy were higher than or equal to single values of 34betaE12.
Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologists.
Vijayalakshmi Ananthanarayanan,Yi Pan,Maria S. Tretiakova,Maria S. Tretiakova,Mahul B. Amin,Liang Cheng,Jonathan I. Epstein,David J. Grignon,Donna E. Hansel,Rafael E. Jimenez,Jesse K. McKenney,Rodolfo Montironi,Esther Oliva,Adeboye O. Osunkoya,Priya Rao,Victor E. Reuter,Jae Y. Ro,Steven S. Shen,John R. Srigley,Toyonori Tsuzuki,Jorge L. Yao,Tatjana Antic,Michael Haber,Jerome B. Taxy,Gladell P. Paner +24 more
TL;DR: It is shown that interpretation of equivocal cases for MPVTI can be made difficult by factors intrinsic to bladder histoanatomy, defined by an irregular MP-perivesical tissue boundary, and factors related to tumor spread.
15
What's new in WHO fifth edition – urinary tract
Eva Comperat,Mahul B. Amin,Daniel M. Berney,Ian A. Cree,S Menon,Holger Moch,George J. Netto,VA Rao,Maria Rosaria Raspollini,M. Rubin,John R. Srigley,Puay Hoon Tan,Satish K. Tickoo,Samra Turajlic,Toyonori Tsuzuki +14 more
TL;DR: The fifth edition of the WHO Blue Book on urological tumours, specifically in the bladder chapter, represents a refinement and update in the classification of bladder tumours building on the aggregate major changes made in previous editions.
15
Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.
George J. Netto,Mahul B. Amin,Eva Comperat,Anthony J. Gill,Arndt Hartmann,Holger Moch,Santosh Menon,Maria Rosaria Raspollini,Mark A. Rubin,John R. Srigley,Puay Hoon Tan,Satish K. Tickoo,Toyonori Tsuzuki,Samra Turajlic,Ian A. Cree,Daniel M. Berney +15 more
TL;DR: In this paper , the authors present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer, arguing that maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring.
15
Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patients.
Masashi Kato,Akihiro Hirakawa,Yumiko Kobayashi,Akiyuki Yamamoto,Ryo Ishida,Osamu Kamihira,Tohru Kimura,Tsuyoshi Majima,Shohei Ishida,Yasuhito Funahashi,Naoto Sassa,Takashi Fujita,Yoshihisa Matsukawa,Tokunori Yamamoto,Ryohei Hattori,Momokazu Gotoh,Toyonori Tsuzuki +16 more
TL;DR: In a multivariate analysis, integrating tertiary Gleason pattern 5 into the ISUP Grade, PSA, and surgical margin status significantly predicted biochemical recurrence (P < 0.0001).
14